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Reﬂections on my career in analytical chemistry and biochemistry
By Charles C. SWEELEY*1,†
(Communicated by Kunihico SUZUKI, M.J.A.)
Abstract: My career has been focused in two major areas, analytical chemistry and
biochemistry of complex lipids and glycoconjugates. Included here are the pioneering work on the
gas chromatography of long-chain sphingolipid bases, carbohydrates, steroids and urinary organic
acids. Mass spectrometry was utilized extensively in structural studies of sphingolipids, fatty acids,
carbohydrates, steroids, urinary organic acids, polyisoprenoid alcohols, and juvenile hormone.
Computer systems were developed for the acquisition and analysis of mass spectra, and were used
for development of automated metabolic proﬁling of complex mixtures of metabolites. Fabry’s
disease was discovered to be a glycosphingolipidosis. Enzymes of lysosomal metabolism of
glycosphingolipids were puriﬁed, characterized, and used in one of the ﬁrst demonstrations of the
feasibility of enzyme replacement therapy in a lysosomal storage disorder (Fabry’s disease).
Extracellular sialidases were studied to evaluate the hypothesis that they might be involved in the
regulation of membrane growth factor receptors. The enzyme for hematoside synthesis was puriﬁed
and characterized.
Keywords: gas chromatography, mass spectrometry, glycosphingolipids, lysosomal
enzymes, sialyltransferase, Fabry’s disease
It might seem odd to some that I would devote
much of my professional career studying the bio-
chemistry of sphingolipids. I say this because my
early training was in chemistry; my doctoral thesis
was entitled “Studies on Streptolidine, a Degradation
Product of Streptothricin”. I deliberately chose the
University of Illinois and Professor Herbert E. Carter
as a mentor for doctoral studies because I wanted to
work in the ﬁeld of natural product chemistry,
speciﬁcally antibiotics. Carter had two laboratories,
one for students working on antibiotics, and one for
students working on sphingosine and sphingolipids.
Little did I know that the research being done in
the “sphingolipids lab” would stick to me and that
I would turn to that ﬁeld soon after I began
postdoctoral work. My thesis research, as well as
that of others in Carter’s lab who worked on this
antibiotic, was eventually published.1)
1. Beginnings
I began postdoctoral work in the Laboratory of
Chemistry of Natural Products at the National Heart
Institute in 1955. It was there, working in Dr. Evan
Horning’s laboratory, that I was to ﬁnd and deﬁne
what would become my major interests. My ﬁrst
project was on the elucidation of the chemical
structure of andromedotoxin, a toxic constituent of
mountain laurel (rhododendron). After several
months, during which time I had made only modest
progress, a group from Nagoya University2) an-
nounced the structure of grayanotoxin, which turned
out to be the same substance.
The next project was to study the mechanism
of a rearrangement reaction occurring when tertiary
amine N-oxides were treated with a complex of ferric
ion and tartaric acid.3) We found that N,N-di-
methylglycine-N-oxide was eﬀectively converted to
sarcosine (N-methylglycine) and formaldehyde at
This research (Figs. 2, 3 and 4) was originally published in
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oxygen atom to one of the methyl groups; transfer
of the oxygen to the methylene atom of the glycine
moiety gave dimethylamine and glyoxylic acid. A
third, pH-dependent reaction yielded carbon dioxide,
formaldehyde and dimethylamine.4) I wanted to see if
the same rearrangement reactions would occur with
nicotine-1′-N-oxide but discovered a complex of
products which probably resulted from oxygen attack
on the adjacent ring carbons as well as the N-methyl
group. In preparing nicotine-1′-N-oxide, I was able to
separate the two diastereoisomers resulting from the
asymmetric quaternary pyrrolidine nitrogen atom
(Fig. 1). Later studies by Phillipson and Handa5)
provide an excellent overview of the chemistry and
enzymology of the nicotine-N-oxides.
Horning had undertaken an experiment with
Charles Dalgliesh (University of London) on the
metabolism of skatole (3-methylindole) in rats and I
was asked to separate and identify the iron-ascorbic
acid catalyzed oxidation products of skatole. This
turned out to be interesting in the sense that the
oxidation products, 4-, 5-, 6-, and 7-hydroxyskatoles,
could be completely separated by sequential elution
from silicic acid columns with 6% benzene-chloroform
solvent, each giving a diﬀerent color with Van den
Bergh’s reagent, diazotized sulfanilic acid. It was
thus determined that the enzymatic oxidation
product of skatole was 6-hydroxyskatole.6)
An unexpected, career-altering opportunity
came to me when Horning ordered the ﬁrst gas
chromatograph at the National Institutes of Health
and I was given the task of setting up this machine
(Barber-Colman Model 10). Our ﬁrst work with this
new technique was for studies of lipid metabolism,
largely following studies in England and U.S.
(Lipsky, Callen and others) on the use of polyester
liquid phases to separate fatty acid methyl esters.7)
Later, I set out independently to apply gas-liquid
chromatography (GC) to other lipids. We reported a
new method to analyze sphingolipid bases in sphingo-
myelin and glycosphingolipids by conversion of these
long-chain bases to aldehydes with periodate and
separation by GC on a siliconized Celite coated with
polyethylene glycol-glutarate.8),9) Human plasma
sphingomyelin was found to contain sphingosine,
dihydrosphingosine, and two unknown bases which
were later shown to be sphinga-4,14-dienine and
hexadecasphing-4-enine.9)–11)
A new method for the preparation of stationary
liquid phases for GC had been developed in our
laboratory, called the “solution-coating” method,7) by
which we could make column packings containing
much lower amounts of liquid phase than had
previously been thought to be possible. This in turn
allowed us to separate larger molecules and at lower
temperatures, decreasing thermal degradation during
GC. Horning suggested that we try to resolve steroids
on one of these columns and this turned out to be
the key to opening a new ﬁeld. We reported the
GC behavior of several androstane-, pregnane-, and
cholestane-based steroids on a polyethylene glycol-
iso-phthalate column12) and introduced the use of a
General Electric silicone gum, called SE-30.13),14)
I left the National Heart Institute in 1960 to
take an academic appointment in the Department
of Biochemistry and Nutrition at the University of
Pittsburgh, in the Graduate School of Public Health.
I shall always be grateful for the opportunity to have
worked with Evan Horning at NIH. His encourage-
ment and wisdom were instrumental in the early
development of my career.
2. Gas chromatography
When I arrived in Pittsburgh I was awarded a
grant from NIH to study the biochemistry of lipids.
Included in the budget was money to acquire the
Barber-Colman Model 10 gas chromatograph with
the Lovelock argon ionization detector.
2-1. Steroids. Our ﬁrst paper was on the GC of
steroids, detailing the response of the argon detector
as a function of structure.15) It was discovered that
the observed molar response was dependent on the
number and nature of functional groups, total oxygen
content having the greatest eﬀect. We pointed out
that the application of GC to quantitative analyses of
steroids would require calibration with each of the
steroids in the mixture.
2-2. Fatty acids. We were interested in the
lipids present in the adrenal gland since this is where
many of the oxidative steps occur in the conversion
N
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Fig. 1. Diastereoisomers of nicotine-1′-N-oxide.
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procedure for locating double bonds in polyenoic
fatty acids from adrenal lipids by periodate-perman-
ganate oxidation and GC16) and reported the
occurrence of a novel fatty acid (7,10,13,16-docosa-
tetraenoic acid), which we called adrenic acid since it
seemed to be in abundance only in (canine) adrenal
gland.17)
2-3. Carbohydrates. In those early days in
Pittsburgh, Bill Wells and I used to drive to the
university together to discuss biochemistry and to
give our wives a vehicle for shopping. One day, we
were talking about Wells’ development of a gas
chromatographic method for the analysis of bile
acids, using trimethylsilyl (TMS) derivatives. It
occurred to us that this reagent might be used to
convert carbohydrates to volatile derivatives. By
noon of that day, Wells in his laboratory in the
medical school, and I in my laboratory in the
Graduate School of Public Health, had independently
shown that we could separate the anomeric forms of
both glucose and galactose as their TMS derivatives
at a relatively low GC column temperature. We
asked Ronald Bentley, a faculty colleague in my
department, to join us in a comprehensive study of
the GC behavior of carbohydrates since he was the
local carbohydrate expert. Over the next several
months, the three of us along with two postdoctoral
fellows in Wells’ lab, Masami Makita and Toyoshi
Katagi, determined the GC retention times of
nearly100 carbohydrates (TMS derivatives) on a
polar polyethylene glycol-succinate column and a
nonpolar silicone gum, SE-52.18)–20) Extending these
studies to other carbohydrate-containing com-
pounds, we described a method for the determination
of the carbohydrate composition of neutral glyco-
sphingolipids and gangliosides by GC.21)
3. Fabry’s disease
I was fortunate at about this time to be
introduced to a University of Pittsburgh colleague
in the Pathology Department, Bernard Klionsky. He
was giving me a tour of his laboratory and told me
about a rare genetic disorder called Fabry’s disease,
supposedly a sphingomyelin disorder as reported by
Scriba.22) I was pleased that he was willing to give me
a piece of formalin-ﬁxed kidney from a Fabry patient.
I was by then well-equipped with the techniques
needed to characterize sphingolipids.
3-1. Novel glycosphingolipids and classiﬁca-
tion as a sphingolipid storage disease. It did not
take long to ﬁnd that this kidney contained abnormal
amounts of two novel glycosphingolipids, which were
partially characterized as a galactosyl-1,4-galactosyl-
1,4-glucosylceramide (GL-3) and a galactosyl-1,4-
galactosylceramide.23) There were no other abnormal
neutral lipids or phospholipids in the sample. Thus, it
was concluded that Fabry’s disease, an X-linked
metabolic disease, should be classiﬁed as a sphingo-
lipidosis. The structural comparison of the GL-3 in
Fabry’s disease with those of globoside, a tetra-
hexosyl neutral glycosphingolipid discovered by
Yamakawa and Suzuki in the stroma of erythro-
cytes24) and lactosylceramide, which had been found
in the neutral glycosphingolipid fraction of human
plasma,25) suggested the possibility that GL-3 is an
intermediate in the metabolism of globoside. My
thoughts turned to methods which might be used
to prove this supposition and to determine whether
the abnormal amounts of GL-3 in Fabry’s disease
resulted from an abnormality in the biosynthetic
pathway or from a deﬁciency of a galactosidase
involved in the metabolism of globoside.
3-2. Stereochemistry of GL-3 (globo-triao-
sylceramide). In 1971, we reported the anomeric
conﬁgurations of the glycosidic linkages in GL-3 from
Fabry kidney.26) We were mistaken in assigning an
nmr peak for the terminal galactose as a O-conﬁg-
uration. This galactosidic linkage was shown to be in
the ,-conﬁguration in several laboratories.27)–30) An
accurate historic account on the chemistry of GL-3
can be found in Sweeley et al.31) The complete
chemical structure of GL-3, consistent with the other
glycolipids in the globo family of neutral glycosphin-
golipids, is galactopyranosyl-,1-4-galactopyranosyl-
O1-4-glucopyranosyl-O1-1′-ceramide.
3-3. Structural studies of other glycosphingo-
lipids. Structural studies of glycolipids include
reports on a glycolipid from Aspergillus niger,32) the
structure of a ceramide tetrahexoside hapten from
rat lymphosarcoma,33) a pentaglycosylceramide from
canine intestine and kidney,34) the sphingolipid
composition of human platelets,35) and structures of
the glycosphingolipids of membrane fractions of
normal and transplanted canine kidney.36)
3-4. Stable isotope-labeled glucose for meta-
bolic studies. We wanted to do in vivo metabolic
studies of the globo-type glycosphingolipids in Fabry
patients but concluded that use of radioactively
labeled tracers was not feasible. Stable isotope-
labeled sugars were just becoming available and we
obtained a sample of perdeuteroglucose (2H7-glucose)
from Merck, Sharpe and Dohme in Montreal. Analy-
sis of mixtures of the TMS derivatives of the protium
C. C. SWEELEY [Vol. 86, 824and deuterium forms gave GC peaks that were
slightly wider than those of either sugar alone,
suggesting the possibility of a chromatographic
isotope eﬀect. We needed GC columns with greater
resolving power (theoretical plates) to test this
possibility. Capillary columns were just then becom-
ing known, mainly in Europe, and were not
commercially available. Bentley and I therefore
decided to make a long packed column from 1/8
inch (i.d.) copper tubing. We packed 8 foot sections
of this tubing with 3% SE-30 stationary phase and
coupled 6 sections together with Swagelok ﬁttings.
The result was a GC column with approximately
40,000 theoretical plates. Mixtures of TMS glucose
and glucose-d7 were completely resolved by this
column in an F & M Model 400 gas chromatograph,
with retention times of about 153 minutes for the
protium form.37) Curiously, the peak for the deute-
rium labeled glucose was somewhat broader than
that of the protium form (31,000 plates for the
deuterium form versus 40,000 plates for the protium
form). It was interesting that the deuterium-labeled
form of glucose (O-anomer) eluted from the GC
column before the protium form even though it had
the higher molecular weight (547 vs 540 for the TMS
derivatives). We demonstrated that one could use
this GC column to determine the relative amounts of
labeled and unlabeled glucose from metabolic studies
down to as low as 0.5% of the labeled species. Other
groups were reporting chromatographic isotope
eﬀects at about this same time; a detailed study of
the chromatographic isotope eﬀect was reported by
Peter Klein.38) We concluded from studies of band
broadening factors and gas and liquid phase diﬀusion
coeﬃcients that separation of the protium and
deuterium forms could be attributed to diﬀerences
in vapor pressure and diﬀerential solubilities in the
liquid phase.39) We were unable to account for the
band broadening diﬀerences.
3-5. Levels of globo-type glycosphingolipids.
Returning to the problem of neutral glycosphingo-
lipid metabolism in patients with Fabry’s disease,
there were several avenues that needed to be pursued
in addition to the use of stable isotopes. Dennis
Vance, a graduate student in my laboratory, was
interested in this project as his dissertation research.
He analyzed the levels of neutral glycosphingolipids
in normal40) and Fabry plasma and red cells.41) The
circulating level of the GL-3 was elevated about
three-fold in the plasma of all Fabry patients
(hemizygotes) studied and also was elevated in two
female heterozygotes. The red cell levels of globoside
were reduced in the Fabry patients while the amount
of GL-3 was normal. There was little if any
digalactosylceramide in either plasma or red cells of
the Fabry patients. This substance had been shown
by Martensson to be a constituent of the glycolipid
fraction in normal kidney.42)
3-6. Chromatographic isotope eﬀect in GC of
TMS derivatives of deuterium-labeled glucose.
Having concluded that we would have to use a stable
isotope to study glycosphingolipid metabolism in
Fabry’s disease, Vance set out to select a suitable
isotope-labeled glucose as a substrate for these
studies while I was leaving for Stockholm (1965) to
determine how to utilize the newly developed LKB
combined GC-mass spectrometer (LKB-9000) for our
work. I had submitted a supplement to my NIH grant
requesting funds to purchase this instrument before I
began my sabbatical in Sweden. In Ragnar Ryhage’s
laboratory at the Karolinska Institute I was intro-
duced to the LKB-9000 prototype and given permis-
sion to use this instrument for my research. I had the
good fortune to have the assistance of a young
medical student from Columbia University, Ian Fries,
and a visiting professor from St. Louis University,
William Elliott, to work with me on this project. The
ﬁrst thing we did was to take mass spectra as
frequently as we could during the elution of a 50/50
mixture of TMS protium and d7 glucoses from a 2-
meter 3% SE-30 column (approximately 15 second
intervals). The band width was about 2 minutes so
that we were able to obtain about 10 mass spectra.
Collecting the mass spectra with an oscillographic
recorder, I measured the intensities of several ions for
the protium and d7 forms, and plotted ion intensity
versus time. As suspected from our earlier studies by
GC, the d7 form eluted before the protium form, with
about 30 seconds diﬀerence in retention time. Armed
with this result, I approached Ryhage and told him it
would not be possible to use GC-MS to determine
isotope ratios because they were changing through-
out the elution of the mixture. After substantial
deliberation among Ryhage’s engineers, they came up
with an answer, which was to switch the accelerating
voltage back and forth between two values chosen to
focus two ions, one for the protium form and one for
the d7 form. Fries built the device, we demonstrated
that it worked, and thus was born one of the earliest
reports on selected ion monitoring even though we
called it the accelerating voltage alternator and did
not give a name to the method,43) which has since
become widely used and called various names
including mass fragmentography.
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and erythrocyte globo-type neutral glyco-
sphingolipids in Fabry’s disease. The biosynthesis
and metabolism of plasma glycosphingolipids was
studied in a patient with Fabry’s disease, using 6,6-
2H2-glucose44) as a tracer, and subsequently in a pig,
using uniformly 14C-labeled glucose.45),46) Table 1
shows the mean micromolar levels of each of the
globo-type neutral glycosphingolipids in normal and
Fabry plasma.40),41) The incorporation of glucose into
these glycosphingolipids in a Fabry patient and a
control was measured by GC-MS following the
infusion of 35g of 6,6,-2H2-glucose with a 5g priming
dose into each subject, using the ion intensities at
m/z 200 and m/z 202 from mass spectra of the
2,3,4,6-tetra-O-acetyl methyl glucosides, represent-
ing the glucose moiety of the glycolipids. Maximum
incorporation of the labeled glucose occurred in all
of the glycolipids about 48 hours after glucose
infusion, and the label disappeared at logarithmic
rates in all of the glycosphingolipids except the Fabry
GL-3 (globotriaosylceramide) (Table 1). Our results
strongly suggested that the accumulating GL-3 in
Fabry plasma was not derived from a site of
biosynthesis (presumably liver) of the other neutral
glycosphingolipids.44)–46)
3-8. Metabolism of neutral glycosphingo-
lipids in porcine plasma and erythrocytes.
Dawson and Tao obtained the same results in porcine
plasma, which contained the same mixture of neutral
glycosphingolipids as were present in human plas-
ma.45),46) Maximum incorporation of 14C-labeled
glucose occurred in the plasma lipids about 24 hours
after injection of 5mCi of glucose into young
Yorkshire pigs. After about 9 days the radioactivity
had disappeared from all of the plasma glycolipids.
Label in the erythrocyte lactosylceramide, GL-3 and
globoside persisted, however, until about 60 days
when the labeled erythrocytes reached senescence. At
that time, label reappeared in the plasma pools of
lactosylceramide, GL-3 and globoside. Glucosylcer-
amide behaved diﬀerently, however, because of a
dynamic equilibrium between the plasma and eryth-
rocyte pools of this lipid. We concluded from these
studies that erythrocyte lacotosylceramide, GL-3 and
globoside were synthesized in bone marrow and
incorporated into the erythrocyte membrane, where
they remained until the erythrocytes reached sen-
escence, when these glycosphingolipids were lost from
the membrane and appeared in plasma pools without
breakdown and re-synthesis somewhere. By compar-
ing the amount of radioactive glucose in the plasma
and erythrocyte pools at maximum incorporation at
24 hours and 60 days, it was clear that the major
source of the plasma neutral glycosphingolipids was
globoside from the erythrocyte.
4. Structural studies and enzymatic synthesis
of sphingolipid bases
Studies on the chemistry and biosynthesis of
long-chain aliphatic bases from sphingolipids contin-
ued in my laboratory at the University of Pittsburgh
and at Michigan State University, where I moved in
1968. Gaver reported a new method for the meth-
anolysis of sphingolipids and direct determination of
the long-chain bases by GC of the trimethylsilylated
derivatives47) and the N-acetyl-O-trimethylsilylated
derivatives.48) Using the LKB-9000, Polito worked
out a method to determine the positions of double
bonds in unsaturated long-chain sphingolipid bases
by mass spectrometry of the osmium tetroxide
oxidation products by GC-MS of the N-acetyl-O-
trimethylsilyl derivatives,49) which gave character-
istic fragmentation at the vicinal trimethylsilyloxy
groups derived from double bonds. Tetradecasphing-
4-enine and hexadecasphing-4-enine were found to be
the principal long-chain bases in larvae and adults of
Musca domestica,50) and iso-branched-chain sphinga-
nines were the long-chain bases in phospho-sphingo-
lipids from Bacteroides melaninogenicus.51) In the
scorpion we discovered eicosasphinga-4,11-dienine
and eicosasphing-11-enine.52)
The biosynthesis of sphingolipid bases was a
very active ﬁeld in the 1950’s and 1960’s and the
mechanism had been shown to involve a pyridoxal-
phosphate (PLP) catalyzed condensation of serine
with palmitoyl CoA and concomitant loss of carbon
dioxide. We were interested in details of the
Table 1. Micromolar levels of neutral glycosphingolipids in
plasma and incorporation of 6,6-2H2-glucose in normal and
Fabry’s disease plasmas
Glycolipida Plasma Pool Sizeb % 6,6-2H2-Glucosec
Normal Fabry Normal Fabry
Glucosylceramide 9.8 7.8 0.8 0.8
Lactosylceramide 5.5 4.7 0.8 1.6
Globotriaosylceramide 2.1 7.6 0.4 0.1
Globoside 2.8 3.1 0.7 0.4
aGlobotriaosylceramide is the name given in the nomenclature
for glycolipids109) for the Fabry GL-3.
bMicromolar concentrations in plasma.
cPercent incorporation of labeled glucose into the glucose
moiety of the plasma glycosphingolipid.
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biosynthesis of sphinganine, sphing-4-enine and 4-
hydroxysphinganine. Since it had been shown by
Stodola that Hansenula ciferrii produced fully and
partially acetylated extracellular sphingolipid bases
in relatively large amounts, Thorpe chose this species
of yeast for her doctoral studies.53) The principal
products were tetracetyl-4-hydroxysphinganine and
triacetylsphinganine. It had been reported that the
synthesis of 4-hydroxysphinganine in whole yeast
cells was similar to the pathway for sphing-4-enine
and sphinganine in animal systems.54) We were
interested in the origin of the oxygen atoms in these
long-chain bases and used 18O-labeled water and 18O-
labeled molecular oxygen for these studies. We were
able to show that none of the three oxygen atoms in
4-hydroxysphinganine was derived from molecular
oxygen. Curiously, the incorporation of 18O from
labeled water was nearly as predicted for C-3 but
almost none was incorporated at C-4, leaving us to
conclude that perhaps the C-4 oxygen atom was
derived in yeast from another source in the
medium.53) Previous studies had not ruled out the
possibility that 3-oxosphinganine might be an
intermediate in the biosynthesis of long-chain bases.
We synthesized the 3-oxo products of sphinganine
and sphing-4-enine from their N-acetyl derivatives by
selective oxidation at C-3 with chromic anhydride
in a mixture of dry benzene and pyridine (1:1) and
reported their mass spectral behavior.54) As a
doctoral dissertation project, Polito chose to examine
the incorporation of various deuterium-labeled pal-
mitates into sphinganine and sphing-4-enine.55) One
purpose of this work was to determine whether
sphing-4-enine is an obligatory intermediate in the
synthesis of 4-hydroxysphinganine in yeast. It was
found that perdeuteropalmitate (2H31-palmitate) was
incorporated into 4-hydroxysphinganine with loss of
only one deuterium atom, excluding sphing-4-enine
and 3-oxosphing-4-enine as intermediates since the 4-
hydroxysphinganine would be labeled with 29 deute-
rium atoms (Fig. 2). We then synthesized 2R and 2S,
and 3R and 3S monodeuteropalmitates and incu-
bated them with a cell-free particulate fraction from
yeast (H. ciferri). The results showed that the pro-R-
hydrogens at C-2 and C-3 of palmitate are removed
in the formation of sphing-4-enine, which is consis-
tent with a mechanism involving an antiperiplanar
elimination process, presumably from 3-oxosphinga-
nine.55) Finally, the yeast incorporated (S)-[2-2H1]
palmitate into 4-hydroxysphinganine with retention
of the deuterium atom whereas deuterium was
completely lost from (R)-[2H1]-palmitate in the
conversion. The hydroxylation step to 4-hydroxy-
sphinganine therefore proceeds with retention of
conﬁguration at C-4 of the precursor base
(Fig. 3).55) Finally, Hammond, a postdoctoral asso-
ciate, studied the biosynthesis of unsaturated
sphingosines in cell-free extracts of oysters, which
Hayashi and Matsubara had shown to contain
sphinga-4,8-dienine.56) The primary objective in
Hammond’s study was to determine at which step
in the biosynthesis the double bonds are introduced,
at the fatty acid stage or a long-chain base. Using
GC-mass spectrometry to identify the bases, and
incubations with 14C- and 3H-labeled serine and
palmitate, with and without coincubation with
sphinganine, sphing-4-enine or 3-oxosphinganine,
we showed clearly that desaturation to the mono-
and di-unsaturated long-chain bases occurred with
3-oxosphinganine, followed by reduction to
sphing-4-enine and sphinga-4,8-dienine.57) Finally,
Krisnangkura and I established that the ,-hydrogen
atom of serine was lost in the synthesis of sphinga-
nine in rat microsomal fractions, using [2,3,3-2H3]-
serine as substrate, from which we concluded that the
mechanisms of 3-oxosphinganine synthesis involves
the replacement of the ,-hydrogen atom and the
carboxyl group of serine in the PLP complex by a
proton and the palmitoyl group (Fig. 4).58)
CD3(CD2)14CO~SCoA + serine (PLP)
CD3(CD2)12
O
C
NH2
CH2OH
H
C
1) X-OOH
2) NADPH
C
D OH
C
HO H
C
NH2
CH2OH
CD3(CD2)12
(R)
(S )
(S )
CD2
H
D D
C
CD2
Fig. 2. Conversion of [2H31]-palmitic acid to 4-hydroxysphinga-
nine in yeast with loss of one deuterium atom from C-2 of
palmitate.55)
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I can discuss only brieﬂy our extensive studies of
lysosomal enzymes of glycosphingolipid metabolism,
post-translational processing reactions in their bio-
synthesis, and enzyme replacement therapy in
Fabry’s disease.
5-1. ,-Galactosidase A and ,-galactosidase
B. Dean was able to purify ,-galactosidase A and
,-galactosidase B to homogeneity from human
liver59)–61) and showed that ,-galactosidase B is
active with ,-N-acetylgalactosamine-containing sub-
strates and probably functions in cells as an ,-
galactosaminidase.61) Sung puriﬁed ,-N-acetylgalac-
tosaminidase from porcine liver.62) For use in enzyme
replacement therapy, we partially puriﬁed ,-galac-
tosidase A from Cohn Fraction IV-1 of human
plasma on a scale suﬃcient to provide enough
enzyme for therapy.63),64)
5-2. Post-translational processing of oligo-
saccharide chains of ,-galactosidases A and B.
While I was on sabbatical at MIT in Robbins’
laboratory, I undertook a study of the synthesis of
the carbohydrate chains of ,-N-acetylgalactosamini-
dase in cultured human ﬁbroblasts, using [2-3H1]-
mannose and 32Pi as substrates.65) We concluded
from these studies that post-translational reactions
led to high-mannose oligosaccharide moieties on the
enzyme and that a precursor contained phosphoryl-
ated residues. In contrast, the N-linked oligosaccha-
ride chains of ,-galactosidase A were found to
contain both high-mannose and complex, sialylated
chains in the enzyme obtained from cultured Chang
liver cells.66)
5-3. Enzyme replacement therapy in Fabry’s
disease. A pilot study of enzyme replacement was
studied with splenic and plasma forms of ,-galacto-
sidase A in two brothers with Fabry’s disease.67) Six
doses of the enzyme were administered by intra-
venous infusion over a 117-day period. The circulat-
ing half-life of the splenic enzyme was about 10
minutes whereas that of the plasma isozyme was
about 70 minutes, presumably because the plasma
form was more highly sialylated.67) Both isozymes
decreased the level of plasma GL-3 to approximately
50% of pre-infusion levels, the plasma form having a
more prolonged eﬀect on the level of GL-3. There
were no immunological consequences from the multi-
ple injections of these enzymes. Desnick has since
extended these studies to many more patients
and developed a bioengineered ,-galactosidase A
that is now on the market and being used to treat
patients.68)
5-4. Enzymatic synthesis of GM3 ganglioside
(hematoside). Studies by Hakomori on the
regulation of membrane-bound growth factor recep-
tors by GM3 ganglioside69) prompted me to become
interested in the enzymatic synthesis of this ganglio-
side and in its catabolism by extracellular sialidases,
hypothesizing that they might be involved in the
metabolism of GM3 on the cell membrane. For
substrates in the puriﬁcation of the sialyltransferase
(SAT-1) from rat liver Golgi apparatus,70) lacto-
sylceramide was synthesized chemically by
Kanemitsu71) and CMP-[14C4,5,6,7,8,9]-sialic acid of
high speciﬁc activity was obtained from New
England Nuclear. The enzyme activity was extracted
from Golgi-enriched microsomal fractions with lauryl-
dimethylamine oxide, chromatographed ﬁrst on an
aﬃnity column of CMP-hexanolamine-Sepharose and
then on an aﬃnity column of lactosylceramide
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Fig. 3. Conversion of S-[2H1]-palmitate to 4-hydroxysphinganine
by hydroxylation of 3-oxosphinganine and with loss of the pro-R
hydrogen of serine and retention of conﬁguration.55)
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on an immunoaﬃnity column containing an anti-
SAT-1 monoclonal antibody. Overall puriﬁcation
was about 37,000-fold yielding a single spot on gel
electrophoresis. SAT-1 speciﬁcity was determined
with various neutral and sialo-glycosphingolipids and
sialo-glycoproteins. Lactosylceramide was the pre-
ferred sialic acid acceptor although glucosylceramide,
galactosylceramide and asialo-GM1 ganglioside
served as substrates to a lesser extent.70)
5-5. Metabolism of GM3 ganglioside. This
ganglioside was ﬁrst isolated from horse erythrocytes
in 1951 by Yamakawa and Suzuki72) and was shown
to consist of sphingosine, fatty acid, glucose, galac-
tose and N-glycolylneuraminic acid (NeuGc). Sub-
stitution of the amino group of neuraminic acid was
shown to be species-speciﬁc, human erythrocytes
containing N-acetylneuraminic acid (NeuAc).73) We
were interested in the metabolism of GM3 ganglioside
by extracellular sialidases as a possible mechanism
for the regulation of their role when bound to growth
factor receptors.74),75) Although we were able to
measure the activity of a GM3 sialidase in the
cultured medium of human ﬁbroblasts76) we could
not tell whether the sialidase in the medium or a
membrane-bound sialidase was involved in the turn-
over of GM3 ganglioside. The soluble sialidase had an
optimum activity at pH 6.5 and increased with cell
Fig. 4. Loss of deuterium from C-2 of [2H3]-serine precedes decarboxylation and addition of the palmitoyl group in its conversion to
3-oxosphinganine in whole cells of yeast (Hansenula ciferri).58)
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support of our hypothesis about the turnover of GM3
in these cells, we found that GM3 labeled with 14Ci n
the sialic acid residue and 3H in the long-chain base
(ceramide) lost the label preferentially in the sialic
acid residue with little or no loss of label in the
ceramide moiety.76),77)
These results were extended by Ogura, who
showed that the addition of lactosylceramide (100
µM) to the ﬁbroblast culture medium increased DNA
synthesis three-fold within 24 hours and cell density
two-fold after 48 hours.78) We concluded that these
results were compatible with a mechanism by which
the proliferation of human ﬁbroblasts is regulated by
the relative levels of GM3 and lactosylceramide in the
plasma membrane.78)
6. Mass spectrometry data systems
and metabolic proﬁling
I would now like to summarize brieﬂy the work
that Jack Holland and I did over many years on
computer systems for the acquisition and analysis of
mass spectral data. Our work together began shortly
after I joined the faculty at Michigan State Univer-
sity. Our ﬁrst computers were a PDP-8i and PDP-8e
from DEC. Programming was done in machine
language by a group of students (many of them were
honors undergraduates). Our ﬁrst paper was on the
development of an on-line computer system for single
focusing mass spectrometry.79) This was followed by
a report on computer-controlled multiple ion detec-
tion in combined gas chromatography-mass spec-
trometry (GC-MS)80) and development of a computer
system for selected ion monitoring of multi-compo-
nent mixtures by computer control of accelerating
voltage and magnetic ﬁeld strength.81) This allowed
investigators to determine several substances in
mixtures at the very high sensitivity obtained by
selected ion monitoring. The next step was to develop
methods for the automated determination of many
substances in a mixture and this led to the develop-
ment of MSSMET, a computer system for metabolic
proﬁling.82)–87) We utilized metabolic proﬁling to
examine the urinary organic acid fraction in natural
early-onset insulin-dependent diabetic dogs88) and in
studies of the turnover of [U-14C]-glucose into various
metabolites in lactic acidemias.89) This technique was
utilized not only in studies of urinary organic acids
but also in the analysis of urinary steroids.90)
6-1. Sound as a sense of perception in GC
analyses. Metabolic proﬁling was also extended to a
new and novel detection system using musical sounds
instead of graphs or tables to analyze normal and
abnormal samples of urine.91) Intensities at the apex
of each GC peak were converted to frequencies and
played on a digital keyboard, higher notes reﬂecting
greater concentrations of metabolites. This was one
of the ﬁrst reports on the use of sound as a sense of
perception in the ﬁeld of analytical chemistry and
became known whimsically in the press world-wide as
“musical urines.”
6-2. Time array detection by time-of-ﬂight
mass spectrometry. During the 1980’s a group of
scientists in the Chemistry and Biochemistry Depart-
ments at Michigan State University were working on
the development of a detector that could be used
with time-of-ﬂight mass spectrometry for high-speed
gas chromatographic analyses. The system they
developed was capable of collecting up to 10,000
mass spectra per second. We were interested in the
utilization of this new tool in metabolic proﬁling
studies and demonstrated its capabilities with
organic acid metabolites from urine, collecting 10
scan ﬁles per second and allowing proﬁling analyses
to be carried out in about 15 minutes instead of more
than 80 minutes required by capillary GC with
magnetic sector instruments.92)
7. Collaborations
Mass spectrometers with GC inlets were not
widely available in the 1960’s and 1970’s and I had
always made our instrumentation available for
service analyses as well as collaborations when
interpretations of mass spectral data were requested.
Several of these collaborations were especially nota-
ble and should be discussed here.
7-1. Fast–atom bombardment mass spec-
trometry. I was fortunate to have the opportunity
to work with Yoko Ohashi on one of the early papers
on the use of fast-atom-bombardment mass spec-
trometry (FAB-MS) of gangliosides and neutral
glycosphingolipids. She and Doug Gage at Michigan
State University extended our earlier work on the
analysis of trimethylsilylated glycosphingolipids us-
ing electron-impact MS, demonstrating that FAB-
MS in the positive and negative modes is useful in
determining structural features with prominent mo-
lecular ions and fragment ions to determine long-
chain base composition and saccharide sequences up
to and including GM2 ganglioside.93)
7-2. Insect juvenile hormone. In 1966, Roller
and Dahm (University of Wisconsin Zoology
Department) visited my laboratory at the Univer-
sity of Pittsburgh with a lipid called juvenile
C. C. SWEELEY [Vol. 86, 830hormone, which they had isolated from the abdo-
mens of adult male Hyalophora cecropia, the giant
silkworm moth.94) Using GC-MS for analyses of the
hormone, we found a molecular ion at m/z 294 and
fragment ions at M-18 and M-32 suggesting an
empirical formula of C18H30O3. Catalytic hydro-
genation yielded a product with a molecular ion
at m/z 284, suggesting an empirical formula of
C18H36O2. These results could be interpreted to
mean that juvenile hormone contained three double
bonds or rings including an oxygen atom that was
eliminated by hydrogenation (either an epoxide or
a tertiary alcohol group). Fragment ions of the
hydrogenation product also indicated that the
hormone was a methyl ester (m/z 74) with
branching at C-7. The position of the labile oxygen
and its nature were determined by GC-MS of the
products obtained by catalytic hydrogenation with
a poisoned catalyst (palladium on barium sulfate
with triethylamine). Several days after Roller and
Dahm had returned to Wisconsin, I concluded that
the mass spectral data were consistent with the
structure shown in Fig. 5. This structure was
unusual and unexpected and Roller delayed pub-
lication until it was conﬁrmed by nmr spectroscopy
(Barry Trost), which also allowed assignment of the
trans conﬁgurations to the two double bonds.95)
This structure was later conﬁrmed by chemical
synthesis in several laboratories.
7-3. Polyisoprenoid alcohols. The peptido-
glycan of bacterial cell walls is synthesized by a
sequence of reactions involving a membrane-bound
phospholipid which is bound to the oligosaccharide
chain during extension of the carbohydrate moiety.96)
Strominger called me from the University of
Wisconsin (Pharmacology Department) to ask if I
would help him identify this lipid. Not having
analyzed molecules of the size of phospholipids I
asked him to carry out acid-catalyzed methanolysis
and I would see if I could identify the products
(presumed to be fatty acids) by GC-MS. When the
sample arrived, I was unable to ﬁnd any fatty acid
methyl esters by GC-MS and so I tried to analyze the
sample in the direct probe of the LKB9000. A mass
spectrum was obtained for a substance with an
unusually high molecular weight, showing a very
weak molecular ion at m/z 766 and a fragment ion at
M-18 (m/z 748). There were clusters of fragment ions
separated by 68 mass units and a very intense ion
at m/z 68, which were taken to be derived from a
polyisoprenoid alcohol composed of 11 isoprene and a
terminal primary alcoholic functional group.97) The
chemical structure of this undecaprenol is shown in
Fig. 6. A similar alcohol, called bactoprenol, had
been isolated from lactobacilli.98) This same poly-
isoprenoid alcohol was simultaneously reported to be
involved in the biosynthesis of the lipopolysaccha-
rides in the bacterial cell wall of Salmonella.99) I
identiﬁed this polyprenol as well in hydrolysates sent
to me by Lennarz, who found it to be a structural
intermediate in mannan synthesis in Micrococcus
lysodeikticus.100) A much larger polyisoprenol (doli-
chol), containing -20 isoprene units, was discovered
by Behrens and Leloir as a carrier in the synthesis
of the oligosaccharide chains of glycoproteins in rat
liver.101)
7-4. Kallikreins. At a meeting in Japan in the
1980’s, I met with the late Professor Hiroshi Moriya
of the Science University of Tokyo. He asked if I
would be interested in a project on kallikrein, a
glycoprotein in human plasma. I agreed and was
pleased to have visits to my laboratory by several
of his young scientists over the next several
years.102),103)
7-5. An inhibitor of sphing-4-enine biosyn-
thesis and mass spectrometry of complex oligo-
saccharides. Finally, Professor Fumito Matsuura
(Fukuyama University) and I have enjoyed a long
and fruitful association, beginning with his postdoc-
toral work in my laboratory in 1979. He and
Soltysiak worked on the synthesis of D,L-,-ﬂuoro-
palmitic acid104) and showed that this fatty acid is
a strong inhibitor of sphing-4-enine synthesis.105)
He was involved in our studies of permethylated
oligosaccharide chromatography106) and was the
leader in structural studies of urinary oligosaccha-
rides from patients with mannosidosis.107) He also
developed a method for the analysis of asparagine-
linked neutral oligosaccharides from ,1-acid glyco-
protein, bovine fetuin, human chorionic gonadotro-
O
O
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Fig. 5. Chemical structure of juvenile hormone from Hyalophora
cecropia.95)
CH3C
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Fig. 6. Chemical structure of bacterial polyisoprenoid alcohol
involved in peptidoglycan synthesis.97)
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reported the elution proﬁles of 39 oligosaccharide
derivatives on TSKgel Amide 80 and Wakosil 5C18-
200 columns.108)
Conclusions
By now the work I have described is ancient
history. Such progress has been made over the past
15 years that my studies are but faint memories in
the dusty archives of science. But I lived in exciting
times, times that marked the beginnings in most of
the areas of my research. It was the beginning of gas
chromatography, nearly the beginning of mass
spectrometry in the biomedical sciences, the begin-
ning of chemistry and metabolism of sphingolipids,
and certainly the beginning of what we now know
about intermediary metabolism in man. Our gen-
eration provided a foundation upon which modern
investigation in these ﬁelds has grown and pros-
pered. It was indeed exciting, and I am fortunate to
have known and considered as my friends some of
the giants in chromatography and sphingolipid
research.
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Proﬁle
Charles Sweeley was born in Williamsport, Pennsylvania in 1930. He is a graduate
of the University of Pennsylvania (B.S., Chemistry, 1952) and the University of Illinois
(Ph.D., Biochemistry, 1955). He began his research career at the National Institutes of
Health in Dr. Evan Horning’s laboratory, where together they established the ﬁrst gas
chromatography laboratory at NIH. They pioneered the development of gas chromatog-
raphy for the separation of steroids and he was the ﬁrst to report the gas chromatography
of long-chain sphingolipid bases. In 1960, he joined the faculty in biochemistry at the
University of Pittsburgh, Graduate School of Public Health. Continuing his work on
biochemical applications of gas chromatography, he reported the chemistry of several
new sphingolipid bases, and pioneered with colleagues the gas chromatography of
carbohydrates in a paper in 1963 that drew international attention and was one of the 500 most cited papers in the
1960’s. He published one of the ﬁrst papers on selected ion monitoring in combined gas chromatography-mass
spectrometry. Combining his knowledge about the separation of fatty acids, carbohydrates and sphingolipid bases,
he discovered the biochemical basis of the X-linked genetic disorder, Fabry’s disease, reporting the partial
structures of two novel glycosphingolipids isolated from the Fabry kidney. He determined the levels of the globo
type glycosphingolipids in normal and Fabry plasma and erythrocytes and studied their biosynthesis and
metabolism using stable isotope-labeled glucose as a tracer. He proposed the correct chemical structure of the insect
juvenile hormone in 1967 and established the chemical structure of the polyisoprenoid alcohol involved in
peptidoglycan biosynthesis using combined gas chromatography-mass spectrometry. In 1968 he accepted an
academic position as Professor of Biochemistry at Michigan State University where he continued his studies on the
biochemistry of sphingolipids. His interests during that time included studies of the lysosomal enzymes of
glycosphingolipid metabolism, enzyme replacement therapy in Fabry’s disease, post-translational processing
reactions in lysosomal enzyme synthesis, eﬀects of tumor promoters on glycolipid metabolism, regulation of
glycolipid metabolism in normal and transformed cells in culture, and isolation and characterization of glycolipid
antigens. He collaborated extensively with Holland on biomedical applications of gas chromatography and mass
spectrometry, leading to the ﬁrst fully automated computer system for mass spectrometry and the development of
metabolic proﬁling of urinary organic acids for disease diagnosis. He was Chairperson of the Department of
Biochemistry at Michigan State University from 1979 to 1985, Guggenheim Fellow in Stockholm in 1970, Michigan
Scientist of the Year in 1988, and University Distinguished Professor in 1990. He was awarded an honorary degree
from Ghent University in Belgium in 1982 and the Anachem Award from the American Chemical Society in 2001.
C. C. SWEELEY [Vol. 86, 836